Literature DB >> 11791690

In vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler.

N Y Chew1, H K Chan.   

Abstract

Dry powder inhalers for eformoterol fumarate dihydrate, a long-acting beta-2 agonist for bronchodilation, are currently available as the Foradile Aerolizer and the Oxis Turbuhaler. The two products are different in the formulation, the aerosol production mechanism, and the device resistance to air flow. These disparities are likely to lead to different aerosol characteristics. Our objective was to compare the in vitro performance of these two inhalers in producing eformoterol aerosols. Emitted dose uniformity was measured using a sampling apparatus described in the British Pharmacopaeia. Ten individual doses (dose number 2, 3, 15, 16, 30, 31, 45, 46, 59, and 60) of the entire content (60 doses) were collected from the Aerolizer and the Turbuhaler (six inhalers each). Particle size distribution of the aerosols generated by the two inhalers were measured by a multiple stage liquid impinger at four different air flows (30-120 L/min). Eformoterol collected from the sampling devices was measured by HPLC. Fine particles are those of < or = 1.7-5.0 microm in size in the aerosols obtained by interpolation of the data at the specified air flow. The Aerolizer showed a slight dependence of the emitted dose on the air flow, with the average emitted dose increased from 80% (at 30 L/min) to 90% (at higher flows) of the 12-microg label claim as compared with 60% for the Turbuhaler. When the emitted dose was normalized by the average emitted dose value, the Aerolizer showed less variation in the normalized emitted dose uniformity than the Turbuhaler. At high air flows, 90 and 120 L/min, both inhalers produced similar amounts (4 microg) of fine particles in the aerosol per dose discharged. As the flow as decreased to 30 and 60 L/min, both inhalers produced significantly less fine particles (p < 0.05), with the Oxis Turbuhaler producing lesser amounts than the Foradile Aerolizer. However, due to the different device resistance, comparing the inhaler performance at the same inspiratory effort may be more appropriate. At a comfortable effort of 40 cm H2O, the Foradile Aerolizer would produce a significantly higher fine particle mass in the aerosols. We conclude that the two inhalers were dissimilar in the emitted dose uniformity. The fine particle mass of eformoterol produced by the two inhalers was equivalent at high but not at low air flows. The disparities may be due to the difference in the formulation and the aerosol generation mechanism of the inhalers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11791690     DOI: 10.1089/08942680152744703

Source DB:  PubMed          Journal:  J Aerosol Med        ISSN: 0894-2684


  9 in total

1.  Effects of device and formulation on in vitro performance of dry powder inhalers.

Authors:  Wallace P Adams; Sau L Lee; Robert Plourde; Robert A Lionberger; Craig M Bertha; William H Doub; Jean-Marc Bovet; Anthony J Hickey
Journal:  AAPS J       Date:  2012-04-05       Impact factor: 4.009

2.  Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses.

Authors:  Matthew S Coates; Hak-Kim Chan; David F Fletcher; Judy A Raper
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

3.  A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.

Authors:  John Gar Yan Chan; Anneliese S Tyne; Angel Pang; Hak-Kim Chan; Paul M Young; Warwick J Britton; Colin C Duke; Daniela Traini
Journal:  Pharm Res       Date:  2013-11-16       Impact factor: 4.200

4.  Effect of device design on the aerosolization of a carrier-based dry powder inhaler--a case study on Aerolizer(®) Foradile (®).

Authors:  Qi Tony Zhou; Zhenbo Tong; Patricia Tang; Mauro Citterio; Runyu Yang; Hak-Kim Chan
Journal:  AAPS J       Date:  2013-02-01       Impact factor: 4.009

5.  Medication Tracking: Design and Fabrication of a Dry Powder Inhaler with Integrated Acoustic Element by 3D Printing.

Authors:  Yongquan Li; Adam Bohr; Henrik Jensen; Jukka Rantanen; Claus Cornett; Moritz Beck-Broichsitter; Johan Peter Bøtker
Journal:  Pharm Res       Date:  2020-01-21       Impact factor: 4.200

6.  Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD.

Authors:  Courtney Crim; Michael L Watkins; Eric D Bateman; Gregory J Feldman; Isabelle Schenkenberger; Edward M Kerwin; Catriona Crawford; Krishna Pudi; Shuyen Ho; Charlotte Baidoo; Ramiro Castro-Santamaria
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-03-08

7.  Performance of dry powder inhalers with single dosed capsules in preschool children and adults using improved upper airway models.

Authors:  Sandra Lindert; Antje Below; Joerg Breitkreutz
Journal:  Pharmaceutics       Date:  2014-02-06       Impact factor: 6.321

8.  Inspiratory flows and volumes in subjects with cystic fibrosis using a new dry powder inhaler device.

Authors:  Mark R Elkins; Philip Robinson; Sandra D Anderson; Clare P Perry; Evangelia Daviskas; Brett Charlton
Journal:  Open Respir Med J       Date:  2014-01-24

9.  Inspiratory Flows and Volumes in Subjects with Non-CF Bronchiectasis Using a New Dry Powder Inhaler Device.

Authors:  Mark R Elkins; Sandra D Anderson; Clare P Perry; Evangelia Daviskas; Brett Charlton
Journal:  Open Respir Med J       Date:  2014-01-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.